JP2016512507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512507A5 JP2016512507A5 JP2016500947A JP2016500947A JP2016512507A5 JP 2016512507 A5 JP2016512507 A5 JP 2016512507A5 JP 2016500947 A JP2016500947 A JP 2016500947A JP 2016500947 A JP2016500947 A JP 2016500947A JP 2016512507 A5 JP2016512507 A5 JP 2016512507A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- alkoxy
- hiv
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- -1 homopiperidinyl Chemical group 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003302 alkenyloxy group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 230000034303 cell budding Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GZKRTCVCPGXHGH-SANMLTNESA-N (2S)-2-[2-[(4-fluorophenyl)methylsulfonylamino]-7-methyl-5-(4-methyl-4-prop-2-enoxypiperidin-1-yl)imidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC2=NC(NS(=O)(=O)CC3=CC=C(F)C=C3)=CN2C(N2CCC(C)(CC2)OCC=C)=C1[C@H](OC(C)(C)C)C(O)=O GZKRTCVCPGXHGH-SANMLTNESA-N 0.000 claims 1
- FYBJIBWIAPHLIY-VWLOTQADSA-N (2s)-2-[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3ON=C(CC=4C=CC=CC=4)N=3)=CN2C=1N1CCC(C)(C)CC1 FYBJIBWIAPHLIY-VWLOTQADSA-N 0.000 claims 1
- IEOMJICAAQPBAE-VWLOTQADSA-N (2s)-2-[2-(5-benzyl-1,3,4-oxadiazol-2-yl)-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3OC(CC=4C=CC=CC=4)=NN=3)=CN2C=1N1CCC(C)(C)CC1 IEOMJICAAQPBAE-VWLOTQADSA-N 0.000 claims 1
- RSGJTTNSMQLVJM-VWLOTQADSA-N (2s)-2-[2-[4-chloro-5-[(4-fluorophenyl)methyl]-1h-imidazol-2-yl]-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3NC(CC=4C=CC(F)=CC=4)=C(Cl)N=3)=CN2C=1N1CCC(C)(C)CC1 RSGJTTNSMQLVJM-VWLOTQADSA-N 0.000 claims 1
- QJWSOMMSNWFUOW-VWLOTQADSA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C=2N=C3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(N4CCC(C)(C)CC4)N3C=2)=C1 QJWSOMMSNWFUOW-VWLOTQADSA-N 0.000 claims 1
- RQFSNOCDCIQHRC-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3OC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 RQFSNOCDCIQHRC-SANMLTNESA-N 0.000 claims 1
- YFMDMKNSJXLNFI-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 YFMDMKNSJXLNFI-SANMLTNESA-N 0.000 claims 1
- YGEQFICGLUWQBM-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1h-imidazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3NC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 YGEQFICGLUWQBM-SANMLTNESA-N 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780179P | 2013-03-13 | 2013-03-13 | |
| US61/780,179 | 2013-03-13 | ||
| PCT/US2014/022354 WO2014164409A1 (en) | 2013-03-13 | 2014-03-10 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512507A JP2016512507A (ja) | 2016-04-28 |
| JP2016512507A5 true JP2016512507A5 (enExample) | 2017-04-13 |
Family
ID=50771321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500947A Pending JP2016512507A (ja) | 2013-03-13 | 2014-03-10 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9655889B2 (enExample) |
| EP (1) | EP2970273B1 (enExample) |
| JP (1) | JP2016512507A (enExample) |
| CN (1) | CN105008358B (enExample) |
| ES (1) | ES2623777T3 (enExample) |
| WO (1) | WO2014164409A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| PT3107913T (pt) | 2014-02-19 | 2018-09-28 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| US10065953B2 (en) * | 2014-08-27 | 2018-09-04 | VIIV Healthcare UK (No.5) Limited | Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| KR101987994B1 (ko) | 2015-01-28 | 2019-06-11 | 제이엔 테라퓨틱스 | 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법 |
| TWI700284B (zh) | 2015-05-29 | 2020-08-01 | 日商塩野義製藥股份有限公司 | 具有ｈｉｖ複製抑制作用之含氮３環性衍生物 |
| US20180170903A1 (en) * | 2015-07-06 | 2018-06-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| RU2018102554A (ru) * | 2015-07-08 | 2019-08-08 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |
| WO2017025913A1 (en) * | 2015-08-10 | 2017-02-16 | VIIV Healthcare UK (No.5) Limited | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| KR20230051207A (ko) * | 2020-08-14 | 2023-04-17 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | Jak 억제제의 염 형태, 결정형, 이의 제조방법 및 이의 용도 |
| CN113698342B (zh) * | 2021-10-29 | 2021-12-31 | 南京恒远科技开发有限公司 | 一种奥布替尼关键中间体杂环类化合物2,6-二氯烟酸的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR910011852A (ko) * | 1989-12-04 | 1991-08-07 | 폴 디. 매튜카이티스 | 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물 |
| CN1578781A (zh) | 2001-09-26 | 2005-02-09 | 拜尔药品公司 | 用作抗糖尿病药物的1,8－萘啶衍生物 |
| JP2009507795A (ja) * | 2005-08-31 | 2009-02-26 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| ATE541841T1 (de) | 2007-11-15 | 2012-02-15 | Boehringer Ingelheim Int | Inhibitoren der replikation des human immunodeficiency virus |
| ES2402322T3 (es) | 2007-11-15 | 2013-04-30 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| EP2334675B1 (en) * | 2008-09-16 | 2014-03-26 | Csir | Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| SG181423A1 (en) | 2009-12-23 | 2012-07-30 | Univ Leuven Kath | Novel antiviral compounds |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| KR20140003438A (ko) | 2010-11-15 | 2014-01-09 | 카톨리에케 유니버시테이트 루벤 | 항바이러스성 축합 헤테로사이클릭 화합물 |
| EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2014
- 2014-03-10 WO PCT/US2014/022354 patent/WO2014164409A1/en not_active Ceased
- 2014-03-10 JP JP2016500947A patent/JP2016512507A/ja active Pending
- 2014-03-10 US US14/770,702 patent/US9655889B2/en not_active Expired - Fee Related
- 2014-03-10 ES ES14725559.0T patent/ES2623777T3/es active Active
- 2014-03-10 CN CN201480013594.8A patent/CN105008358B/zh not_active Expired - Fee Related
- 2014-03-10 EP EP14725559.0A patent/EP2970273B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512507A5 (enExample) | ||
| JP2016512558A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| JP2017526748A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2015524841A5 (enExample) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2016528301A5 (enExample) | ||
| JP2016535795A5 (enExample) | ||
| JP2016516692A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2011500806A5 (enExample) | ||
| JP2016510038A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| JP2007519649A5 (enExample) | ||
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| JP2015514808A5 (enExample) | ||
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| JP2018522927A5 (enExample) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2014532754A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |